No insider purchase over the last 90 days. The latest was filed 16 Jun 2025.
Every trade that managers of Paysign, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Finance & Banking sector. 14 insiders have disclosed 49 filings since 18 October 2025.
The flow runs one way only: 17 sales worth €6.1M, from 8 insiders, and no purchase. The totals exclude 1 filing filed without an amount. One trade stands out by size: a sale of €1.5M from Newcomer Mark, disclosed on 7 August 2026, or 0.25% of market capitalisation.
Compared with its exchange (5,814 companies, median 19 filings), a count of 49 filings is above the norm. Our records for Paysign, Inc. go back to 2021, with 11 purchases and 52 sales on the open market in total. The 10-K for the year ended 31 December 2025 shows 82.0 m USD of revenue and 7.6 m USD of net income.
Typically, a trade is published a median of 4 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
In the same sector, recent insider purchases at First Guaranty Bancshares, Inc. and BCB Bancorp Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
+6 other insiders
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 159 declarations
Paysign, Inc. is a United States-based company listed on the NASDAQ market (United States) and focused on prepaid card payment solutions and integrated payment processing services. Headquartered in Henderson, Nevada, the company was incorporated on August 24, 1995. For French-speaking investors, Paysign should be viewed less as a traditional bank and more as a niche fintech and payments infrastructure provider: it designs, launches, and operates physical and virtual prepaid card programs, together with the related processing stack, for clients that need fast disbursement, traceability, and strong compliance controls.
The company’s business model is primarily B2B/B2B2C. Historically, Paysign has served corporate, consumer, and government customers with prepaid card products and processing services. More recently, management has emphasized two strategic growth engines: patient affordability programs for the pharmaceutical industry and donor compensation solutions for plasma collection centers. This verticalized approach places Paysign inside regulated workflows where payment accuracy, operational reliability, and user experience matter materially. Paysign positions itself as a full-service partner, able to handle program design, card issuance, transaction processing, operations, and certain support functions.
From a competitive standpoint, Paysign operates in a fragmented market that includes large payment processors, card issuers, gift-card specialists, and fintech vendors focused on specific verticals. Its competitive edge is more about specialization than sheer scale: the company targets end markets where customized program architecture and deep operational integration create stickiness. Management also highlights a portfolio of millions of prepaid cards, which suggests a meaningful installed base within its niche.
Geographically, the business is mainly concentrated in the United States, although its services may support customers with broader operating footprints. The company remains headquartered in Henderson, Nevada, and reported approximately 226 employees and independent contractors at year-end 2025.
Recent developments are important for the investment case. On March 24, 2026, Paysign reported full-year 2025 revenue of $82.0 million, up 40.5% year over year, with margin expansion driven by an improved mix. The company also reported growth in plasma center count and active patient affordability programs, reinforcing the momentum in its highest-growth verticals. In addition, Paysign continues to appear in a steady flow of SEC Form 4 insider transaction filings, which keeps the market attentive to changes in insider ownership and trading activity.
Purchases our model currently ranks for the recommendations list.
All recommendationsInsider filings
Over the last 90 days, 38 filings published between 31 July and 14 October 2026: 13 sales for €5.5M. 25 other filings (not open-market purchases or sales: grants, options, plans, sale notices, block transfers). Largest amounts: Newcomer Mark (CEO), sales of €2.6M; Ngo Michael C (Chief Innovation Officer), sales of €1.6M; Herman Joan M (EVP, Operations), sales of €621k.
Summary written automatically from public filings, without human review. General information, identical for every reader: it is not investment advice or a recommendation to buy or sell. Investing involves a risk of capital loss. Generated on 15 October 2026 (UTC)
| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2025 | 82.0 m USD | 7.6 m USD | 0.13 USD | 10-K |
| Dec 2024 | 58.4 m USD | 3.8 m USD | 0.07 USD | 10-K |
| Dec 2023 | 47.3 m USD | 6.5 m USD | 0.12 USD | 10-K |
| Dec 2022 | 38.0 m USD | 1.0 m USD | 0.02 USD | 10-K |
| Dec 2021 | 29.5 m USD | -2.7 m USD | -0.05 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.